Introduction
============

Chronic kidney disease (CKD) is a global health burden and an independent risk factor for cardiovascular disease (CVD) ([@b1-ijsc-12-304]). CKD is characterized by reduced nephron number, intra-glomerular hypertension ([@b2-ijsc-12-304]), oxidative stress induction and interstitial inflammation with subsequent fibrosis ([@b3-ijsc-12-304]). CKD is associated with sustained activation of the renin-angiotensin system (RAS), which augments renal inflammatory and pro-oxidant states and affects the cardiovascular system, inducing vascular resistance, arterial calcification, cardiovascular remodelling and inflammation ([@b4-ijsc-12-304]).

Bone marrow-derived mesenchymal stem cells (BM-MSCs) are adult multipotent non-haematopoietic stem cells that have potential roles in regeneration and tissue repair ([@b5-ijsc-12-304]) and can be obtained and cultured without significant ethical concerns ([@b6-ijsc-12-304]). Additionally, MSCs have mitogenic, anti-apoptotic and angiogenic influences ([@b7-ijsc-12-304]).

MSCs have been used in some acute renal failure models, such as in glycerol-induced ARF or in renal ischaemic/reperfusion, and were able to differentiate into tubular epithelial cells and to promote epithelial proliferation ([@b8-ijsc-12-304]). In addition, Villanueva et al. ([@b9-ijsc-12-304]) added that MSCs were able to attenuate glomerulosclerosis, interstitial fibrosis and the progression of CKD in rats.

In contrast, Gheisari et al. ([@b10-ijsc-12-304]) could not confirm the beneficial or protective effects of MSCs in chemically induced AKI by glycerol and cisplatin. Huuskes et al. ([@b11-ijsc-12-304]) claimed that although MSCs can accelerate renal repair following acute injury, the establishment of fibrosis during CKD may affect their regeneration capacity.

Therefore, the current study was planned to detect the ability of BM-MSCs to improve kidney function and cardiac function in adult rats with established CKD.

Materials and Methods
=====================

Animals
-------

This study was performed on female adult albino rats weighing 160\~200 gm at the start of the study that were purchased from the Egyptian Organization for Biological Products and Vaccines (VACSERA). Rats were kept in the Animal House of the Physiology Department, Faculty of Medicine, Ain Shams University under standard boarding conditions. Food and water access were provided ad libitum.

Ethics declarations
-------------------

Ethical standards were adhered to in this research. In this work, animals were not exposed to unnecessary pain or stress, and animal manipulation was performed with maximal care and hygiene. The surgical procedure was performed under anaesthesia to avoid the induction of pain in animals. Disposal of the animal remains was achieved by incineration.

This work was approved by the Ain Shams Faculty of Medicine Research Ethics Committee under Federal Wide Assurance number 000017585.

Experimental groups
-------------------

Rats were allocated into 3 groups containing 15 rats each.

1.  **Group I:** Sham-operated control group that was supplemented with a single I.V. infusion of phosphate buffer solution in the rat tail vein for 4 weeks.

2.  **Group II:** Untreated subtotally nephrectomized group: subtotal (five-sixths) nephrectomy was performed, and 4 weeks later, rats were supplemented with a single I.V. infusion of phosphate buffer solution in the rat tail vein.

3.  **Group III:** Treated subtotally nephrectomized group: subtotal (five-sixths) nephrectomy was performed, and 4 weeks later, rats were supplemented with a single I.V. infusion of 0.5 ml of phosphate buffer solution (PBS) containing bone marrow-derived stem cells (1.5×10^6^) in the rat tail vein with a modified protocol from Yuen et al. ([@b12-ijsc-12-304]).

Five-sixths nephrectomy technique
---------------------------------

The 5/6 nephrectomy operation was performed according to methods described by Addis and Lew ([@b13-ijsc-12-304]) and was modified to a two-stage operation with removal of one kidney followed, after one week, by excision of the upper and the lower poles of the other kidney using a 2-0 chromic catgut suture loop. Anaesthesia was induced and maintained using a mask containing a cotton pad moistened with ether. The muscle wound was closed with 2-0 chromic catgut thread, and the skin was closed with silk sutures. Bivatracin topical antibiotic spray (ECAP CO., Egypt) was applied to the wound soon after the operation and daily until healing was complete.

Bone marrow-derived stem cell treatment
---------------------------------------

Isolation, culture and incubation of BM-MSCs were performed according to McFarlin et al. ([@b14-ijsc-12-304]) at the Medical Research Center of Ain Shams University. Bone marrow cells were isolated from the femurs and tibiae of weaned normal male rats aged from 6 to 8 weeks and were suspended in tubes containing 10 ml of complete culture media, Dulbecco's modified Eagles medium (DMEM) (Lonza Company, Swiss).

After centrifugation, the bone marrow cell pellet was suspended in 10 ml of complete culture media in a T-75 flask and incubated at 37°C, 5% carbon dioxide (CO2) and 85% humidity. Later, using inverted microscopy, MSCs were identified by their spindle-shaped morphology, adherence and colony-forming capacity. MSCs were distinguished from other bone marrow cells by negative expression of CD34 and positive expression of CD44 in immune staining, as described by Li et al. ([@b15-ijsc-12-304]) ([Fig. 1](#f1-ijsc-12-304){ref-type="fig"}).

The MSC count was determined, and after reaching confluence at day 10, trypsin EDTA was added for 2 min at 37°C to detach the cells. Trypan blue staining was performed. Viable cells that were not stained with trypan blue were counted using a haemocytometer according to this equation (average number of cells per small square× dilution factor×10^4^) ([Fig. 1](#f1-ijsc-12-304){ref-type="fig"}).

Measurement of arterial blood pressure
--------------------------------------

Rat arterial blood pressure (systolic, diastolic and mean) was determined using the non-invasive small animal tail blood pressure system (NIBP200A, Biopac systems Inc; USA).

Experimental procedure
----------------------

Body weight and arterial blood pressure were measured periodically and at the end of the experimental period (4 weeks after treatment or 8 weeks after nephrectomy or sham operation). Blood pressure was measured using a non-invasive rat tail cuff sphygmomanometer blood pressure system (NIBP200A). On the day of sacrifice, ECG tracing was recorded using bipolar limb leads with a recording speed of 25 mm/sec by an ECG recorder (Cardimax Fx-2111, Fukuda Denshi Co., Ltd., Japan). Measurements were made for heart rate, P-R interval, QRS complex voltage and duration, observed Q-T interval (Q-TO) and Q-Tc (the corrected Q-TO for the heart rate effect according to Goldschlager and Goldman ([@b16-ijsc-12-304]):
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Furthermore, a midline abdominal incision was made to expose and cannulate the abdominal aorta. The collected blood samples were centrifuged, and the separated plasma was then pipetted into clean storage tubes and stored at −80°C for subsequent determination of plasma creatinine and urea levels.

Isolated heart study
--------------------

Hearts were excised and perfused in a Langendorff preparation with the standard Krebs-Henselite Bicarbonate (KHB) buffer, pH 7.4, equilibrated with O2:CO2 (95%:5%) at 37°C ([@b17-ijsc-12-304]). After a 20-min stabilization period, baseline cardiac activities were assessed by recording the heart rate (HR), peak developed tension (PT), time to peak tension (TPT) and half relaxation time (HRT) using an isometric force transducer (UGO BASILE S.R.L., Model 7004-F, Serial N. 101014, Data EVO 14543, Italy) connected with a USB cable to a recorder (UGO BASILE S.R. L. Biological Research Apparatus 21036, Model 17304, Serial N. O448A15, Italy) and to a computer with I Worx LabScribe2 Data Recording and Analysis Software.

An isolated rat heart apex was attached by a clip to a transducer placed vertical to the heart with the distance adjusted to obtain the best recording of tension; the initial tension was 2 gm, and then, the transducer was kept in position without change during the whole period of recording. The baseline myocardial flow rate (MFR) and myocardial flow rate per 100 mg of left ventricle (MFR/LV, ml/min/100 mg) were recorded.

Then, total global ischaemia was induced by stopping the delivery of perfusion fluid to the heart by a stopcock for 30 min. The heart responses, MFR and MFR/LV were recorded at 5, 15 and 30 min of reperfusion following 30 min of total global ischaemia.

Determination of kidney and heart weights
-----------------------------------------

Twenty-four hours after renal reperfusion, the left kidneys of each rat and whole heart were washed in normal saline, dried by filter paper and cleaned of fat and fibrous tissue. Cardiac chambers were separated, and all tissues were weighed on a 5-Digit-Metler balance (AE 163). Kidney weight was expressed in (g), and the kidney weight/body weight (KW/BW) ratio was calculated. Whole heart and cardiac chamber weights were expressed as absolute values in (mg) as well as cardiac indices (absolute weight/body weight ratio, in mg/g).

PCR detection of male-derived MSCs
----------------------------------

Genomic DNA was extracted from the rat kidney and heart tissue homogenate in each group using the Wizardt Genomic DNA Purification Kit (Promega, Madison, Wisconsin). The presence or absence of the sex determination region on the male Y chromosome (sry) gene in recipient female rats was assessed by PCR as previously described ([@b18-ijsc-12-304]) to amplify a product of 104 base pairs (bp). PCR products were separated using 2% agarose gel electrophoresis and stained with ethidium bromide. Positive (rat male genomic DNA) and negative (female rat genomic DNA) controls were included in each assay.

Biochemical analysis
--------------------

Serum samples were stored at −80°C. Then, using an enzymatic colorimetric technique, we measured serum creatinine levels according to the Jaffé reaction ([@b19-ijsc-12-304]) and serum urea levels according to the modified Urease Berthelot reaction ([@b20-ijsc-12-304]) with kits supplied by Diamond Diagnostics Company, GmbH (Germany).

The results are expressed as the mean±standard error and were statistically analysed according to Armitage and Berry ([@b21-ijsc-12-304]).

Results
=======

The results of the present study are displayed in [Table 1](#t1-ijsc-12-304){ref-type="table"}\~[4](#t4-ijsc-12-304){ref-type="table"} and [Fig. 2](#f2-ijsc-12-304){ref-type="fig"}\~[4](#f4-ijsc-12-304){ref-type="fig"}. The results are expressed as the mean±SEM.

Changes in body weight percentage and kidney weight
---------------------------------------------------

As shown in [Table 1](#t1-ijsc-12-304){ref-type="table"}, the body weight percentage change was significantly reduced in untreated subtotally nephrectomized rats compared to sham-operated control rats (p\<0.01), but after stem cell treatment, the body weight percentage change was significantly increased (p\<0.001) compared to that in the untreated rats to a level that was not significantly different from that of the control rats. In addition, the remnant kidney tissue weight was increased significantly in the treated subtotally nephrectomized group compared to both the untreated subtotally nephrectomized group and the sham-operated control group (p\< 0.001 for both), indicating that MSCs can decrease cellular apoptosis.

Changes in heart weight values
------------------------------

Absolute left ventricular weight (LV), LV/BW and WH/BW indices were significantly higher in the untreated subtotally nephrectomized group (p\<0.05; p\<0.001 and p\<0.01, respectively) than in the sham-operated control group, denoting left ventricle hypertrophy. Upon stem cell treatment, both LV/BW and WH/BW ratios were not significantly decreased compared to those in the untreated nephrectomized group, although those values were still significantly higher than those of the controls ([Table 1](#t1-ijsc-12-304){ref-type="table"}).

Kidney function tests
---------------------

As shown in [Table 1](#t1-ijsc-12-304){ref-type="table"}, plasma levels of creatinine and urea were significantly elevated in the untreated subtotally nephrectomized group compared to the sham-operated control group (p\<0.001 for both), denoting renal function impairment, whereas following stem cell treatment, those levels were significantly decreased compared to those of the untreated subtotally nephrectomized group (p\<0.001 for both), although they were still significantly higher than those in the sham-operated control group (p\<0.05 for both).

Changes in systolic, diastolic and mean arterial blood pressure
---------------------------------------------------------------

As shown in [Fig. 2](#f2-ijsc-12-304){ref-type="fig"}, systolic, diastolic and mean arterial blood pressure values in nephrectomized rats were significantly increased after 4 weeks (p\<0.001 for all) and 8 weeks (p\<0.001, 0.01 and 0.001, respectively) compared to the sham-operated control group. Elevated blood pressure reflects deteriorated kidney functions. Stem cell treatment caused a significant decrease in the 8 week values of systolic, diastolic and mean arterial blood pressure compared to those of the untreated subtotally nephrectomized rats (p\<0.001, p\<0.05 and p\<0.001, respectively).

A significant positive correlation was detected between serum creatinine and systolic and diastolic blood pressure (p\<0.001, p\<0.05).

Electrocardiographic changes
----------------------------

[Table 2](#t2-ijsc-12-304){ref-type="table"} shows that in untreated nephrectomized rats, HR, QRS duration and voltage were significantly reduced (p\<0.05, p\<0.001 and p\<0.01) while Q-To and Q-Tc intervals were prolonged (p\<0.001 for both) compared to those in the control group. Stem cell treatment significantly increased the HR (p\<0.05), prolonged the PR interval and QRS duration and increased QRS voltage (p \<0.001 for all) as well as significantly shortened the Q-To and Q-Tc intervals (p\<0.001 for both) compared to those in untreated nephrectomized rats.

Isolated perfused hearts studies
--------------------------------

Chronotropic activity is illustrated in [Table 3](#t3-ijsc-12-304){ref-type="table"}, in which the treated subtotally nephrectomized group showed a significant increase in HR values at 5, 15 and 30 min of reperfusion compared to both untreated subtotally nephrectomized rats and sham-operated control rats (p\<0.01, \< 0.05 and \<0.05, respectively, for both).

Inotropic activity is illustrated in [Table 4](#t4-ijsc-12-304){ref-type="table"}
---------------------------------------------------------------------------------

Compared to the pre-ischaemia baseline values, PT and peak tension per left ventricular weight (PT/LV) values were significantly decreased (p\<0.001) in all studied groups at 5, 15 and 30 min of reperfusion, while the TPT, HRT and contraction time (CT) were all significantly prolonged in the untreated nephrectomized group compared to the other groups (p\<0.05, 0.01 and 0.001 for all, respectively).

As shown in [Table 4](#t4-ijsc-12-304){ref-type="table"}, the PT and PT/LV values after 30 min of reperfusion (p\<0.01 and p\<0.05 for both, respectively) were significantly decreased in untreated nephrectomized rats compared to the sham-operated control rats. Compared to those in the untreated group, stem cell treatment significantly increased the PT values at pre-ischaemia baseline and after 15 and 30 min of reperfusion (p\<0.01, p\<0.05 and p\<0.001) and the PT/LV value a 30 min of reperfusion (p\<0.05)

As shown in [Table 4](#t4-ijsc-12-304){ref-type="table"}, the TPT and CT were significantly prolonged in the untreated nephrectomized group at 15 and 30 min of reperfusion (p\<0.01, p\<0.001 and p\<0.05, p\<0.01, respectively), but stem cell treatment significantly shortened all TPT values (p\<0.01, p\< 0.01, p\<0.001 and p\<0.001), the half relaxation value at 30 min of reperfusion (p\<0.05) and the CT values at 15 and 30 min of reperfusion (p\<0.001 for both).

Myocardial flow rate
--------------------

In all the studied groups, there were significant decreases in the MFR and MFR/LV at 5, 15 and 30 min of reperfusion compared to their baseline pre-ischaemia values, as shown in [Table 3](#t3-ijsc-12-304){ref-type="table"}.

PCR detection of male-derived MSCs
----------------------------------

The 104-bp band of the Y chromosome marker (sry gene) was expressed in the kidney and the heart homogenate of the treated female rats, assuring BM-MSC homing to these tissues ([Fig. 3](#f3-ijsc-12-304){ref-type="fig"}).

Histopathological examination
-----------------------------

### Renal parenchyma

As shown in [Figure 4](#f4-ijsc-12-304){ref-type="fig"}, untreated rat kidney sections revealed hypertrophied and congested glomerular tufts with distended Bowman's space together with atrophy of other glomerular tufts. Additionally, there was evident cystic dilatation and distension with proteinaceous material in some renal tubules accompanied by necrosis of other renal tubules. Additionally, renal blood vessels showed marked congestion.

Following treatment, the examined kidney sections revealed a decrease in glomerular hypertrophy with normal renal parenchyma

### Cardiac tissue

Analysis of heart sections showed that the heart of sham control rats contained normal cardiomyocytes. In contrast, the hearts of rats from the untreated group showed intermuscular oedema that resulted in dispersed cardiomyocytes and minor intermuscular inflammatory cell infiltration. However, rat cardiomyocytes from the treated group revealed no histopathological changes compared with normal cardiomyocytes ([Fig. 4](#f4-ijsc-12-304){ref-type="fig"}).

Discussion
==========

The present study portrayed the effect of BM-MSCs on renal and cardiovascular functions in adult rats with established CKD.

In the current study, 5/6 nephrectomy induced renal damage, as evidenced by the significant elevation in plasma urea and creatinine levels and all arterial blood pressure values. Renal damage was confirmed by renal glomeruli and tubule necrosis with compensatory hypertrophy of the remaining glomeruli and tubules, which was similar to the findings by Yuen et al. ([@b12-ijsc-12-304]).

The ensuing uremic state after 5/6 nephrectomy caused anorexia and hyperleptinemia ([@b22-ijsc-12-304]) and inhibited downstream growth hormone signalling ([@b23-ijsc-12-304]), leading to the inability of nephrectomized rats to gain weight, as evidenced by a significant reduction in body weight and its percentage change compared to those of the sham-operated control group.

The pro-inflammatory factors TNF-*α*, IL-1 and IL-6 and pro-fibrotic, anti-angiogenic factors Ang II and reactive oxygen species (ROS) that accompany the uremic state alter endothelial permeability, resulting in endothelial dysfunction. In conjunction with impaired sodium and water excretion, impaired calcium metabolism can elevate blood pressure, leading to ventricular remodelling and hypertrophy ([@b24-ijsc-12-304]). This sequence of events was recorded in this study, in which LV/BW and WH/BW ratios showed a significant increase in the nephrectomized group compared to the control group. In addition, dispersed cardiomyocytes with intramuscular oedema and slight inflammatory cell infiltration was observed.

Moreover, compared to the sham-operated group, the untreated nephrectomized group showed significant decreases in HR, QRS voltage and QRS duration as well as significant prolongation of the Q-To and Q-Tc intervals.

Bradycardia may be the result of the baroreceptor reflex in response to the high arterial blood pressure according to Mary's law or the result of a synergistic action of hyperkalaemia and uremic toxins ([@b25-ijsc-12-304]). A significantly low QRS voltage may result from ischaemia that follows cardiac hypertrophy ([@b26-ijsc-12-304]).

The detected Q-T interval prolongation reflects a combination of hypocalcaemia and increased left ventricular mass arising from chronic hypertension ([@b27-ijsc-12-304]) or may result from gap junction disruption by the pro-fibrotic uremic toxins ([@b28-ijsc-12-304]).

The studied isolated hearts subjected to ischaemia-reperfusion injury showed a decrease in all reperfusion PT, peak tension per left ventricular weight (PT/LV) and MFR values together with prolonged TPT, HRTs and CTs following reperfusion compared to the pre-ischaemia baseline values in all groups and when comparing untreated nephrectomized rats with sham-operated control rats. This observation suggests systolic and diastolic function impairment following ischaemia-reperfusion, especially in untreated nephrectomized rats.

Impaired systolic and diastolic function can be attributed to mitochondrial dysfunction, excess ROS generation and calcium overload concomitant with decreased responsiveness of contractile elements to calcium (calcium paradox) ([@b29-ijsc-12-304]). In addition, following reperfusion, the pH paradox activates calpains that lead to myofibril proteolysis and alter membrane ion channel activity, leading to myocardial stunning ([@b30-ijsc-12-304]). MFR reduction can be explained by atherosclerosis and calcification of coronary arteries in patients with end stage renal disease ([@b31-ijsc-12-304]).

Both systolic and diastolic dysfunction are exacerbated by uraemia, reflecting organ cross-talk, as reported by Yuen et al. ([@b12-ijsc-12-304]), whom demonstrated an elevated left ventricular end-diastolic pressure volume relationship (LV EDPVR) in nephrectomized rats, indicating diastolic dysfunction.

Diastolic dysfunction can result from uremic myocardial remodelling and disturbed myocardial calcium homeostasis ([@b32-ijsc-12-304]). In addition, electrolyte disturbances, uremic toxins and pro-inflammatory cytokines can exert a negative inotropic effect or induce cardiomyocyte apoptosis ([@b33-ijsc-12-304]).

Four weeks following a single BM-MSC injection, plasma urea and creatinine levels and all arterial blood pressure values were significantly decreased, with partial improvement in renal parenchyma histological appearance and a significant increase in the body weight gain percentage change, similar to the results of Abdel Aziz et al. ([@b34-ijsc-12-304]).

Moreover, MSCs modulated cardiac electrophysiological properties, as they significantly increased the HR, P-R interval, QRS voltage and QRS duration and shortened the Q-To and Q-Tc intervals compared to those in the untreated group. Additionally, MSCs improved the chronotropic heart state, as they significantly increased the in vitro recorded HR.

In addition, the significant increase from the pre-ischaemia baseline to the reperfusion values of the PT and PT/LV together with the significant shortening in reperfusion TPT, half relaxation and CT values denotes improved systolic and diastolic function, similar to the report by Yuen et al. ([@b12-ijsc-12-304]).

The ability of BM-MSCs to restore normal renal and cardiac function may be explained by their ability to selectively migrate to and home into injured tissues, as BM-MSCs express receptors for growth factors and chemokines released from inflamed organs ([@b35-ijsc-12-304]).

In the injured organs, BM-MSCs can trans-differentiate into many tissues, such as tubular epithelium, renal mesangial cells, podocytes or even glomerular endothelial cells as well as cardiomyocytes and blood vessel elements ([@b36-ijsc-12-304]). Alternatively, BM-MSCs can fuse with host cells, as reported by Ly and Nattel ([@b37-ijsc-12-304]), whom detected cardiomyocyte-specific markers in MSCs, suggesting electrical coupling of MSCs with native cardiomyocytes, which may reduce the risk of ventricular arrhythmia. Moreover, MSCs have paracrine effects, as they can secrete growth, angiogenic and mitogenic factors such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and IGF-I together with anti-apoptotic and anti-fibrotic factors such as IL-10 and Bc1-2 ([@b34-ijsc-12-304]).

In addition, BM-MSCs show anti-inflammatory and immunosuppressive effects because they can impair the maturation and function of dendritic cells and B-cells and suppress T-cell proliferation and can downregulate pro-inflammatory cytokines such as IL-1*β* and TNF-*α* ([@b34-ijsc-12-304]). Ayatollahi et al. ([@b38-ijsc-12-304]) also highlighted the antioxidant properties of BM-MSCs, which are able to reduce tissue malondialdehyde (MDA) and increase the levels of the antioxidants superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px).

Moreover, MSCs may release extracellular vesicles (EVs) known as exosomes, which deliver genes, micro-RNAs and proteins to recipient cells, mediating MSC paracrine actions ([@b39-ijsc-12-304]).

On the other hand, while a single MSC injection increased the MFR, the difference was not significant; this result may be explained by Papazova et al. ([@b40-ijsc-12-304]), whom postulated that multiple administrations of stem cells would confer benefits over single administration for chronic conditions.

Conclusions
===========

In summary, this study highlighted the potential ability of BM-MSC injection to halt CKD progression, as evidenced by decreased serum urea and creatinine levels and arterial blood pressure after BM-MSC treatment. These data were also supported by the reduction in glomerular hypertrophy. Furthermore, BM-MSCs can improve cardiac electrophysiological properties, as evidenced by the significant increase in QRS voltage and decrease in the QT interval. Additionally, the cardiac inotropic functions were improved; the improvement in systolic function evidenced by increased PT per left ventricular weight and decreased time to peak tension, and the improvement in diastolic function was evidenced by the shortening of the TPT. These data were also supported by the restoration of relatively normal cardiac myocyte morphology, as shown by histopathological examination of cardiac tissue in stem cell-treated nephrectomized rats. Thus, BM-MSCs, due to their proven anti-hypertensive and anti-arrhythmic properties, could have strong therapeutic potential.
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![**(**A) Bone marrow-derived mesenchymal stem cells at culture days 1 and 8. (B) MSCs show negative expression of CD34 and positive expression of CD44 (f 400z×).](ijsc-12-304f1){#f1-ijsc-12-304}

![Initial, 4-week and 8-week (a) systolic blood pressure (SBP), (b) diastolic blood pressure and (c) mean arterial blood pressure values in the three studied groups. \*: Significant difference compared to their initial values as calculated by Student's t-test for paired data. a: Significant difference compared to the sham-operated control (Sham) group as calculated by the LSD at p\<0.05. b: Significant difference compared to the untreated subtotally nephrectomized (untreated STNx) group as calculated by the LSD at p\<0.05.](ijsc-12-304f2){#f2-ijsc-12-304}

![Results of the PCR assay for the male Y chromosome (sry) gene following 2% agarose gel electrophoresis and staining with ethidium bromide. M: DNA 100-bp marker, PC: positive PCR control (male rat genomic DNA), NC: negative PCR control (female rat genomic DNA). Lane 1\~4: MSC-treated group, which was injected with mesenchymal stem cells (MSCs). Lane 5\~8: Control and untreated groups that were not injected with male MSCs.](ijsc-12-304f3){#f3-ijsc-12-304}

![Histopathological changes in 1-Control group: (A) Renal tissues (B) Cardiac muscles. 2-Untreated nephrectomised group (A) Renal tissues showing hypertrophy of the glomerular tufts and congestion of renal blood vessels (B) Cardiac muscle showing intramuscular oedema that caused dispersion of the cardiomyocytes. 3-MSCs treated group (A) Renal tissues showing apparent normal renal parenchyma (B) Cardiac muscles showing regained normal morphology (H&E ×400).](ijsc-12-304f4){#f4-ijsc-12-304}

###### 

The body weight percentage change (BW %change), kidney tissue weight (mg), heart weights, and serum urea and creatinine (mg/dl) levels in the three studied groups: sham-operated control (Sham), untreated subtotally nephrectomized (untreated STNx) and treated subtotally nephrectomized (treated STNx) groups

                                    Sham ([@b15-ijsc-12-304])   Untreated STNx ([@b15-ijsc-12-304])                     Treated STNx ([@b15-ijsc-12-304])
  --------------------------------- --------------------------- ------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  BW% change                        23.02±1.21                  13.31±2.61[a](#tfn2-ijsc-12-304){ref-type="table-fn"}   27.61±1.74[b](#tfn3-ijsc-12-304){ref-type="table-fn"}
  Left kidney remnant weight (mg)   787.14±34.35                737.52±35.69                                            1047.78±53.26[a](#tfn2-ijsc-12-304){ref-type="table-fn"}[b](#tfn3-ijsc-12-304){ref-type="table-fn"}
  LV (mg)                           518.81±11.69                569±16.71[a](#tfn2-ijsc-12-304){ref-type="table-fn"}    588.27±18.17[a](#tfn2-ijsc-12-304){ref-type="table-fn"}
  LV/BW (mg/gm)                     2.09±0.05                   2.47±0.08[a](#tfn2-ijsc-12-304){ref-type="table-fn"}    2.30±0.05[a](#tfn2-ijsc-12-304){ref-type="table-fn"}
  WH/BW (mg/gm)                     3.03±0.09                   3.63±0.18[a](#tfn2-ijsc-12-304){ref-type="table-fn"}    3.37±0.08[a](#tfn2-ijsc-12-304){ref-type="table-fn"}
  Creatinine (mg/dl)                0.47±0.02                   1.17±0.07[a](#tfn2-ijsc-12-304){ref-type="table-fn"}    0.66±0.02[a](#tfn2-ijsc-12-304){ref-type="table-fn"}[b](#tfn3-ijsc-12-304){ref-type="table-fn"}
  Urea (mg/dl)                      33.54±1.31                  67.15±3.47[a](#tfn2-ijsc-12-304){ref-type="table-fn"}   42.85±1.72[a](#tfn2-ijsc-12-304){ref-type="table-fn"}[b](#tfn3-ijsc-12-304){ref-type="table-fn"}

The number of observations is shown in parentheses. All values are expressed as the mean±SEM.

Significant difference between the untreated subtotally nephrectomized (untreated STNx) group and sham-operated control group (Sham) as calculated by the LSD at p\<0.05.

Significant difference between the treated subtotally nephrectomized group (treated STNx) group and the untreated subtotally nephrectom-ized (untreated STNx) group as calculated by the LSD at p\<0.05.

###### 

Electrocardiographic changes in the three studied groups: sham-operated control (Sham), untreated subtotally nephrectomized (untreated STNx) and treated subtotally nephrectomized (treated STNx) groups

                        Sham ([@b15-ijsc-12-304])   Untreated STNx ([@b15-ijsc-12-304])                       Treated STNx ([@b15-ijsc-12-304])
  --------------------- --------------------------- --------------------------------------------------------- --------------------------------------------------------
  Heart rate (bpm)      235.67±5.46                 207.43±12.77[a](#tfn5-ijsc-12-304){ref-type="table-fn"}   232±4.36[b](#tfn6-ijsc-12-304){ref-type="table-fn"}
  PR interval (msec)    91.43±4.04                  80±4.78                                                   104.44±4.73[b](#tfn6-ijsc-12-304){ref-type="table-fn"}
  QRS duration (msec)   40±0                        30.48±2.62[a](#tfn5-ijsc-12-304){ref-type="table-fn"}     40±0[b](#tfn6-ijsc-12-304){ref-type="table-fn"}
  QRS voltage (*μ*v)    695.24±41.68                466.67±47.97[a](#tfn5-ijsc-12-304){ref-type="table-fn"}   750±72.87[b](#tfn6-ijsc-12-304){ref-type="table-fn"}
  Q-To (msec)           129.52±3.81                 172±6.55[a](#tfn5-ijsc-12-304){ref-type="table-fn"}       137.78±4.82[b](#tfn6-ijsc-12-304){ref-type="table-fn"}
  Q-Tc (msec)           258.57±6.10                 323.50±7.69[a](#tfn5-ijsc-12-304){ref-type="table-fn"}    273.33±9.53[b](#tfn6-ijsc-12-304){ref-type="table-fn"}

The number of observations is shown in parentheses. All values are expressed as the mean±SEM.

Significant difference between the untreated subtotally nephrectomized (untreated STNx) group and sham-operated control group (Sham) as calculated by the LSD at p\<0.05.

Significant difference between the treated subtotally nephrectomized group (treated STNx) group and the untreated subtotally nephrectom-ized (untreated STNx) group as calculated by the LSD at p\<0.05.

###### 

Heart rate and Myocardial flow rate/100 mg of left ventricle (MFR/LV, ml/min/100 mg), in the three studied groups: sham-operated control (Sham), untreated subtotally nephrectomized (untreated STNx) and treated subtotally nephrectomized (treated STNx) groups

                           Sham ([@b15-ijsc-12-304])                               Untreated STNx ([@b15-ijsc-12-304])                     Treated STNx ([@b15-ijsc-12-304])
  ------------------------ ------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  HR (bpm)                 160±11.88                                               160.53±15.34                                            184.20±8.56
  Pre-ischaemia baseline                                                                                                                   
  5 min of reperfusion     130.93±15.24                                            132.13±14.53                                            198.53±14.82[a](#tfn9-ijsc-12-304){ref-type="table-fn"}[b](#tfn10-ijsc-12-304){ref-type="table-fn"}
  15 min of reperfusion    134.07±9.57                                             133.87±15.14                                            179.80±13.48[a](#tfn9-ijsc-12-304){ref-type="table-fn"}[b](#tfn10-ijsc-12-304){ref-type="table-fn"}
  30 min of reperfusion    133.33±10.29                                            122.60±14.55                                            170.53±15.19[a](#tfn9-ijsc-12-304){ref-type="table-fn"}[b](#tfn10-ijsc-12-304){ref-type="table-fn"}
  MFR/LV (ml/min/100 mg)                                                                                                                   
  Pre-ischaemia baseline   1.20±0.16                                               1.10±0.09                                               1.20±0.08
  5 min of reperfusion     0.89±0.11[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}   0.97±0.08[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}   0.96±0.07[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}
  15 min of reperfusion    0.78±0.11[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}   0.87±0.09[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}   0.76±0.05[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}
  30 min of reperfusion    0.68±0.10[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}   0.66±0.06[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}   0.66±0.06[\*](#tfn7-ijsc-12-304){ref-type="table-fn"}

Significant difference from their initial values as calculated by Student's t-test for paired data.

The number of observations is shown in parentheses. All values are expressed as the mean±SEM.

Significant difference between the untreated subtotally nephrectomized (untreated STNx) group and sham-operated control group (Sham) as calculated by the LSD at p\<0.05.

Significant difference between the treated subtotally nephrectomized group (treated STNx) group and the untreated subtotally nephrectom-ized (untreated STNx) group as calculated by the LSD at p\<0.05.

###### 

Peak tension (PT) and peak tension per left ventricular weight (PT/LV), Time to peak tension (TPT), half relaxation time (HRT) and contraction time (CT) in the three studied groups: sham-operated control (Sham), untreated subtotally nephrectomized (untreated STNx) and treated subtotally nephrectomized (treated STNx) groups

                           Sham ([@b15-ijsc-12-304])                                Untreated STNx ([@b15-ijsc-12-304])                                                                     Treated STNx ([@b15-ijsc-12-304])
  ------------------------ -------------------------------------------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------
  PT (gm)                  6.28±0.26                                                6.00±0.22                                                                                               7.33±0.42[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[b](#tfn13-ijsc-12-304){ref-type="table-fn"}
  Pre-ischaemia baseline                                                                                                                                                                    
  5 min of reperfusion     4.77±0.33[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}   4.34±0.40[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                  4.86±0.29[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  15 min of reperfusion    4.69±0.39[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}   3.84±0.37[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                  4.97±0.30[b](#tfn13-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  30 min of reperfusion    4.29±0.30[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}   3.07±0.29[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}      5.11±0.30[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[b](#tfn13-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  PT/LV (gm/100 mg)        1.23±0.30                                                1.17±0.27                                                                                               1.19±0.35
  Pre-ischaemia baseline                                                                                                                                                                    
  5 min of reperfusion     0.91±0.28[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}   0.87±0.37[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                  0.79±0.24[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  15 min of reperfusion    0.91±0.35[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}   0.76±0.33[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                  0.84±0.29[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  30 min of reperfusion    0.82±0.27[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}   0.60±0.25[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}      0.83±0.24[b](#tfn13-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  TPT (msec)               113.67±8.27                                              120.33±7.93                                                                                             89±2.14[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[b](#tfn13-ijsc-12-304){ref-type="table-fn"}
  Pre-ischaemia baseline                                                                                                                                                                    
  5 min of reperfusion     133.67±11.07                                             137±11.75[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                  91±3.39[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[b](#tfn13-ijsc-12-304){ref-type="table-fn"}
  15 min of reperfusion    110.33±8.24                                              150.67±12.58[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}   91.67±3.30[b](#tfn13-ijsc-12-304){ref-type="table-fn"}
  30 min of reperfusion    114.33±9.17                                              165.67±11.61[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}   93.33±3.44[b](#tfn13-ijsc-12-304){ref-type="table-fn"}
  HRT (msec)               80.67±7.05                                               67.33±5.16                                                                                              75±2.84
  Pre-ischaemia baseline                                                                                                                                                                    
  5 min of reperfusion     99.33±10.75                                              86.67±6.70[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                 86.67±3.80[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  15 min of reperfusion    97.67±7.86                                               95±8.31[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                    85±2.13[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  30 min of reperfusion    94.33±8.90                                               103.33±6.82[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                83.67±3.67[b](#tfn13-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  CT (msec)                194.33±10.63                                             184.67±10.29                                                                                            164±3.85[a](#tfn12-ijsc-12-304){ref-type="table-fn"}
  Pre-ischaemia baseline                                                                                                                                                                    
  5 min of reperfusion     233±15.90                                                223±14.97[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}                                                  177.67±6.11[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[b](#tfn13-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  15 min of reperfusion    208±12.42                                                243±15.60[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}      176.67±3.92[b](#tfn13-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}
  30 min of reperfusion    208.67±14.70                                             269±12.73[a](#tfn12-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}      177±5.60[b](#tfn13-ijsc-12-304){ref-type="table-fn"}[\*](#tfn14-ijsc-12-304){ref-type="table-fn"}

The number of observations is shown in parentheses. All values are expressed as the mean±SEM.

Significant difference between the untreated subtotally nephrectomized (untreated STNx) group and sham-operated control group (Sham) as calculated by the LSD at p\<0.05.

Significant difference between the treated subtotally nephrectomized group (treated STNx) group and the untreated subtotally nephrectom-ized (untreated STNx) group as calculated by the LSD at p\<0.05.

Significant difference from their initial values as calculated by Student's t-test for paired data.
